This content is from: Capital Markets
Rule change in HK to usher in wave of US IPOs
Changes allowing pre-revenue companies to list on the HKEx means that a number of biotech companies are likely to list on the exchange
To access our in-house intelligence please request a trial here.
Read this article – and more – for a 30 day period.
REQUEST ACCESSAre you already an IFLR subscriber? Login here